Magnetic resonance nano-theranostics for glioblastoma multiforme

Current Pharmaceutical Design

Volumn 21, Issue 36, 2015, Pages 5256-5266

  Yao, Jingwen ^a   Hsu, Chao Hsiung ^a   Li, Zhao ^a   Kim, Tanya S ^a   Hwang, Lian Pin ^b   Lin, Ying Chih ^b   Lin, Yung Ya ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Glioblastoma multiforme; Magnetic resonance; Nano theranostics

Indexed keywords

MAGNETIC NANOPARTICLE; ANTINEOPLASTIC AGENT; MAGNETITE NANOPARTICLE;

ARTICLE; BIOSAFETY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENE THERAPY; CANCER RADIOTHERAPY; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; ELECTRIC FIELD; GENE THERAPY; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERTHERMIA; HYPERTHERMIC THERAPY; MOLECULAR BEACON; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION WEIGHTED IMAGING; PH; PRIORITY JOURNAL; STEM CELL; ANIMAL; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEM; PATHOLOGY; PROCEDURES; THERANOSTIC NANOMEDICINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; THERANOSTIC NANOMEDICINE;

EID: 84947998422     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150923103307     Document Type: Article

References (102)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CACancer J Clin 2012; 62(1): 10-29.
2. rd ed. USA: American Cancer Society 2015.
3. Dunn GP, Rinne ML, Wykosky J, et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012; 26: 756-84.
4. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS Statistical Report: Primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol 2014; 16: iv1-63.
5. Scherer HJ. Structural development in gliomas. Am J Cancer 1938; 34: 333-51.
6. Giese A, Westphal M. Glioma invasion in the central nervous system. Neurosurgery 1996; 39: 235-50.
7. Brat DJ, Castellano-Sanchez AA, Hunter SB, et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004; 64: 920-7.
8. Raza SM, Lang FF, Aggarwal BB, Fuller GN, Wildrick DM, Sawaya R. Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery 2002; 51: 2-12.
9. Hentschel SJ, Lang FF. Current surgical management of glioblastoma. Cancer J 2003; 9(2): 113-25.
10. Zinn PO, Colen RR, Kasper EM, et al. Extent of resection and radiotherapy in GBM: a 1973 to 2007 surveillance, epidemiology and end results analysis of 21,783 patients. Int J Oncol 2013; 42(3): 929-34.
11. Rock K, McArdle O, Forde P, et al. A clinical review of treatment outcomes in glioblastoma multiforme-the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival?. Br J Radiol 2014 [Epub ahead of print].
12. Reardon DA, Rich JN, Friedman HS, et al. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 2006; 24(8): 1253-65.
13. Sathornsumetee S, Rich JN. Antiangiogenic therapy in malignant glioma: promise and challenge. Curr Pharm Des 2007; 13(35): 3545-58.
14. Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol 2014; 9: 1-25.
15. Chamberlain MC. Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol 2011; 5: 117.
16. Kelly PJ. Gliomas: survival, origin and early detection. Surg Neurol Int 2010 [Epub ahead of print].
17. Chamberlain MC. Radiographic patterns of relapse in glioblastoma. J Neurooncol 2011; 101(2): 319-23.
18. De Bonis P, Anile C, Pompucci A, et al. The influence of surgery on recurrence pattern of glioblastoma. Clin Neurol Neurosurg 2013; 115(1): 37-43.
19. Wallner KE, Galicich JH, Krol G, et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989; 16(6): 1405-9.
20. Pirotte BJM, Levivier M, Goldman S, et al. Positron emission tomography- guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery 2009; 64(3): 471-81.
21. Biswas T, Okunieff P, Schell MC, et al. Stereotactic radiosurgery for glioblastoma: retrospective analysis. Radiat Oncol 2009; 4(11).
22. Johnson DR, O'Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 2012; 107: 359-64.
23. Batzdorf U, Malamud N. The problem of multicentric gliomas. J Neurosurg 1963; 20: 122-36.
24. Lammers T, Aime S, Hennink WE, et al. Theranostic nanomedicine. Acc Chem Res 2011; 44(10): 1029-38.
25. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 2010; 21: 797-802.
26. Green MR, Manikhas GM, Orlov S, et al. Abraxane®, a novel Cremophore ®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006; 17: 1263-68.
27. Miele E, Spinelli GP, Miele E, et al. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. Int J Nanomed 2009; 4: 99-105.
28. Stupp R, Tonn JC, Brada M, et al. High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow- up. Ann Oncol 2010; 21(Supp 5): 190-3.
29. Jenkinson MD, Du Plessis DG, Walker C, et al. Advanced MRI in the management of adult gliomas. Br J Neurosurg 2007; 21(6): 550- 61.
30. Baehring JM, Bi WL, Bannykh S, et al. Diffusion MRI in the early diagnosis of malignant glioma. J Neurooncol 2007; 82: 221-5.
31. Weber MA, Zoubaa S, Schlieter M, et al. Diagnostic performance of spectroscopic and perfusion MRI for distinction of brain tumors. Cancer Imaging 2006; 6: S32-41.
32. Roessler K, Donat M, Lanzenberger R, et al. Evaluation of preoperative high magnetic field motor functional MRI (3 Tesla) in glioma patients by navigated electrocortical stimulation and postoperative outcome. J Neurol Neurosurg Psychiatry 2005; 76(8): 1152- 7.
33. Ellingson BM, Malkin MG, Schmainda KM, et al. Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. J Neurooncol 2011; 102(1): 95-103.
34. Tsien C, Galbán CJ, Chenevert TL, et al. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol 2010; 28(13): 2293- 9.
35. Vinogradov E, Sherry AD, Lenkinski RE. CEST: from basic principles to applications, challenges and opportunities. J Magn Reson 2013; 229: 155-72.
36. Jones CK, Schlosser MJ, van Zijl P, et al. Amide proton transfer imaging of human brain tumors at 3T. Magn Reson Med 2006; 56(3): 585-92.
37. Salhotra A, Lal B, Laterra J, et al. Amide proton transfer imaging of 9L gliosarcoma and human glioblastoma xenografts. NMR Biomed 2008; 21(5): 489.
38. Zhou J, Tryggestad E, Wen Z, et al. Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides. Nat Med 2011; 17(1): 130-4.
39. Sagiyama K, Mashimo T, Sherry AD, et al. In vivo chemical exchange saturation transfer imaging allows early detection of a therapeutic response in glioblastoma. Proc Natl Acad Sci 2014; 111(12): 4542-7.
40. Mahmoudi M, Sant S, Wang B, et al. Superparamagnetic iron oxide nanoparticles (SPIONs): Development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev 2011; 63: 24- 46.
41. McCullough BJ, Kolokythas O, Maki JH, et al. Ferumoxytol in clinical practice: implications for MRI. J Magn Reson Imaging 2013; 37(6): 1476-9.
42. Neuwelt EA, Várallyay CG, Manninger S, et al. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neurosurgery 2007; 60(4): 601-12.
43. Peng XH, Qian X, Mao H, et al. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomed 2008; 3(3): 311-21.
44. Deshane J, Garner CC, Sontheimer H. Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J Biol Chem 2003; 278(6): 4135-44.
45. Sun C, Veiseh O, Gunn J, et al. In Vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small 2008; 4(3): 372-9.
46. Sun C, Fang C, Stephen Z, et al. Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles. Nanomedicine 2008; 3(4): 495-505.
47. Veiseh O, Kievit FM, Fang C, et al. Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery. Biomaterials 2010; 31(31): 8032-42.
48. Veiseh M, Gabikian P, Bahrami SB, et al. Tumor Paint: a chlorotoxin: Cy5.5 Bioconjugate for intraoperative visualization of cancer foci. Cancer Res 2007; 67(14): 6882-8.
49. Xie H, Zhu Y, Jiang W, et al. Lactoferrin-conjugated superparamagnetic iron oxide nanoparticles as a specific MRI contrast agent for detection of brain glioma in vivo. J Biomaterials 2011; 32(2): 495-502.
50. Chen K, Xie J, Xu H, et al. Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting. Biomaterials 2009; 30(36): 6912-19.
51. Zhang F, Huang X, Zhu L, et al. Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. Biomaterials 2012; 33(21): 5414-22.
52. Zheng SW, Huang M, Hong RY, et al. RGD-conjugated iron oxide magnetic nanoparticles for magnetic resonance imaging contrast enhancement and hyperthermia. J Biomater Appl 2014; 28(7): 1051-9.
53. Li B, Yuan M, Kim IA, et al. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol- 3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene 2004; 23: 4594-602.
54. Hadjipanayis CG, Machaidze R, Kaluzova M, et al. EGFRvIII antibody conjugated iron oxide nanoparticles for MRI guided convection- enhanced delivery and targeted therapy of glioblastoma. Cancer Res 2010; 70(15): 6303-12.
55. Reddy GR, Bhojani MS, McConville P, et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 2006; 12(22): 6677-86.
56. Nair BG, Nagaoka Y, Morimoto H, et al. Aptamer conjugated magnetic nanoparticles as nanosurgeons. Nanotechnology 2010; 21(45).
57. Wu X, Hu J, Zhou L, et al. In vivo tracking of superparamagnetic iron oxide nanoparticles-labeled mesenchymal stem cell tropism to malignant gliomas using magnetic resonance imaging. J Neurosurgery 2008; 108(2): 320-9.
58. Zhang Z, Jiang Q, Jiang F, et al. In vivo magnetic resonance imaging tracks adult neural progenitor cell targeting of brain tumor. Neuroimage 2004; 23(1): 281-7.
59. Ganta S, Devalapally H, Shahiwala A, et al. A review of stimuliresponsive nanocarriers for drug and gene delivery. J Control Release 2008; 126: 187-204.
60. Murgia S, Bonacchi S, Falch AM, et al. Drug-loaded fluorescent cubosomes: versatile nanoparticles for potential theranostic applications. Langmuir 2013; 29: 6673-9.
61. Caltagirone C, Falchi AM, Lampis S, et al. Cancer-cell-targeted theranosticcubosomes. Langmuir 2014; 30: 6228-36.
62. Ho LC, Hsu CH, Ou CM, et al. Unibody core-shell smart polymer as a theranostic nanoparticle for drug delivery and MR imaging. Biomaterials 2015; 37: 436-46.
63. Zhu XM, Yuan J, Leung KCF, et al. Hollow superparamagnetic iron oxide nanoshells as a hydrophobic anticancer drug carrier: intracellular pH-dependent drug release and enhanced cytotoxicity. Nanoscale 2012; 4: 5744-54.
64. Kievit FM, Wang FY, Fang C, et al. Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. J Control Release 2011; 152: 76-83.
65. Agarwal A, Mackey MA, El-Sayed MA, et al. Remote triggered release of doxorubicin in tumors by synergistic application of thermosensitive liposomes and gold nanorods. ACS Nano 2011; 5: 4919-26.
66. Zhang J, Misra RDK. Magnetic drug-targeting carrier encapsulated with thermosensitive smart polymer: core-shell nanoparticle carrier and drug release response. Acta Biomater 2007; 3: 838-50.
67. Liu HL, Hua MY, Yang HW, et al. Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain. Proc Natl Acad Sci 2010; 107(34): 15205-10.
68. Chen GJ, Wang LF. Design of magnetic nanoparticles-assisted drug delivery system. Curr Pharm Des 2011; 17(22): 2331-51.
69. Dilnawaz F, Singh A, Mewar S, et al. The transport of nonfurfactant based paclitaxel loaded magnetic nanoparticles across the blood brain barrier in a rat model. Biomaterials 2012; 33: 2936-51.
70. Gao H, Wang Y, Chen C, et al. Incorporation of lapatinib into coreshell nanoparticles improves both the solubility and anti-glioma effects of the drug. Int J Pharm 2014; 461: 478-88.
71. Yoo B, Ifediba MA, Ghosh S, et al. Combination treatment with theranostic nanoparticles for glioblastoma sensitization to TMZ. Mol Imaging Biol 2014; 16: 680-89.
72. Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 2002; 43: 33-56.
73. Jordan A, Scholz R, Maier-Hauff K., et al. The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neurooncol 2006; 78: 7-14.
74. Maier-Hauff K, Ulrich F, Nestler D, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol 2011; 103: 317-24.
75. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003; 4(5): 346-58.
76. Li S, Huang L. Nonviral gene therapy: promises and challenges. Gene Ther 2000; 7: 31-4.
77. Kievit FM, Veiseh O, Bhattarai N, et al. PEI-PEG-chitosan copolymer coated iron oxide nanoparticles for safe gene delivery: synthesis, complexation, and transfection. Adv Funct Mater 2009; 19(14): 2244-51.
78. Ito A, Shinkai M, Honda H, et al. Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles. Cancer Immunol Immunother 2003; 52: 80-8.
79. Ito A, Tanaka K, Kondo K, et al. Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma. Cancer Sci 2003; 94(3): 308-13.
80. Paula LB, Primo FL, Jardim DR, et al. Development, characterization, and in vitro trials of chloroaluminum phthalocyanine-magnetic nanoemulsion to hyperthermia and photodynamic therapies on glioblastoma as a biological model. J Appl Phys 2012; 111(7): 07B307.
81. Koo YELK, Reddy GR, Bhojani M, et al. Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev 2006; 58: 1556-77.
82. Greig NH, Daly EM, Sweeney DJ, et al. Pharmacokinetics of chlorambucil- tertiary butyl ester, a lipophilic chlorambucil derivative that achieves and maintains high concentrations in brain. Cancer Chemother Pharmacol 1990; 25(5): 320-5.
83. Lesniak MS. Novel advances in drug delivery to brain cancer. Technol Cancer Res Treat 2005; 4(4): 417-28.
84. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995; 345: 1008-12.
85. Allard E, Passirani C, Benoit JP. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 2009; 30(12).
86. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 2004; 104: 29-45.
87. Chertok B, Moffat BA, David AE, et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials 2008; 29(4): 487-96.
88. Kreuter J, Ramge P, Petrov V, et al. Direct evidence that polysorbate- 80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 2003; 20(3): 409-16.
89. Laurent S, Saei AA, Behzadi S, et al. Superparamagnetic iron oxide nanoparticles for delivery of therapeutic agents: opportunities and challenges. Expert Opin Drug Deliv 2014; 11(9): 1449-70.
90. Li Z, Hsu CH, Dimitrov N, et al. Sensitive imaging of magnetic nanoparticles for cancer detection by active feedback MR. Magn Reson Med 2015; 74: 33-41.
91. Lin YY, Lisitza N, Ahn S, Warren WS. Resurrection of crushed magnetization and chaotic dynamics in solution NMR spectroscopy. Science 2000; 290: 118-21.
92. Huang SY, Wolahan SM, Mathern GW, et al. Improving MRI differentiation of gray and white matter in epileptogenic lesions based on nonlinear feedback. Magn Reson Med 2006; 56: 776-86.
93. Datta S, Huang SY, Lin YY. Contrast enhancement by feedback fields in magnetic resonance imaging. J Phys Chem B 2006; 110: 22071-8.
94. Datta S, Huang SY, Lin YY. The transient dynamics leading to spin turbulence in high-field solution magnetic resonance: a numerical study. J Chem Phys 2006; 124: 154501.
95. Huang SY, Furuyama JK, Lin YY. Designing feedback-based contrast enhancement for in vivo imaging. Magn Reson Mater Phys 2006; 19: 333-46.
96. Datta S, Huang SY, Lin YY. Understanding spin turbulence in solution magnetic resonance through phase space dynamics and instability. Concepts Magn Reson 2006; 28A: 410-21.
97. Huang SY, Chung AP, Lin YY. Visualizing feedback-enhanced contrast in magnetic resonance imaging. Concepts Magn Reson 2007; 30A: 378-93.
98. Huang SY, Yang SS, Lin YY. Sensitivity of feedback-enhanced MRI contrast to macroscopic and microscopic field variations. Magn Reson Med 2009; 61: 925-36.
99. Cunningham CH, Arai T, Yang PC. Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn Reson Med 2005; 53: 999-1005.
100. Zurkiya O, Hu X. Off-resonance saturation as a means of generating contrast with superparamagnetic nanoparticles. Magn Reson Med 2006; 56: 726-32.
101. Seppenwoolde JH, Viergever MA, Bakker CJ. Passive tracking exploiting local signal conservation: the white marker phenomenon. Magn Reson Med 2003; 50: 784-90.
102. Mani V, Briley-Saebo KC, Itskovich VV. Gradient echo acquisition for superparamagnetic particles with positive contrast (GRASP): sequence characterization in membrane and glass superparamagnetic iron oxide phantoms at 1.5 T and 3 T. Magn Reson Med 2006; 55: 126-35.